Therapure Biopharma Inc, a portfolio company of Canadian private equity firm Catalyst Capital Group, has filed a preliminary prospectus with Canadian securities regulatory authorities for an initial public offering. The offering has not yet been priced, however, Bloomberg reported the company is seeking to raise at least $100 million. GMP Securities, CIBC World Markets and National Bank Financial are underwriting the sale. Based in Mississauga, Ontario, Therapure is a biopharmaceutical company focused on the development, manufacture, purification, and packaging of rare and complex biotherapeutics.
Therapure Biopharma Inc. Files Preliminary Prospectus for Initial Public Offering
November 26, 2015
MISSISSAUGA, Ontario–(BUSINESS WIRE)–Therapure Biopharma Inc. today announces that it has filed a preliminary prospectus with securities regulatory authorities in each of the provinces and territories of Canada in connection with a proposed initial public offering (the “Offering”) of its common shares. A copy of the preliminary prospectus is available on SEDAR (www.sedar.com).
The Offering is being made through a syndicate of underwriters co-led by GMP Securities L.P., CIBC World Markets Inc. and National Bank Financial Inc.
The preliminary prospectus contains important information relating to the securities but remains subject to completion or amendment. There will not be any sale or any acceptance of an offer to buy the securities until a receipt for the final prospectus has been issued.
About Therapure Biopharma Inc.
Therapure is a biopharmaceutical company focused on manufacturing complex biologics for its customers and on developing, manufacturing and selling its own blood and plasma-related therapeutic products. Its passion for quality and patient safety underpins everything it does in its three divisions: Therapure Biomanufacturing, an award-winning contract development and manufacturing division; Therapure Biologics, a division focused on using its proprietary PlasmaCap EBA™ technology to develop a portfolio of plasma-derived pharmaceutical products; and Therapure Innovations, a proprietary therapeutics and platform technologies research and development division. Therapure operates out of two facilities located in Mississauga: a 130,000 sq. ft. cGMP facility that includes biomanufacturing, research and quality control laboratories and is built to meet FDA (US), HPFB (Canada), EMA (Europe) and MHRA (UK) standards, and a new 43,000 sq. ft. facility housing 30,000 sq. ft. of cGMP warehouse.
Visit www.therapurebio.com for more information about Therapure Biopharma Inc. and its divisions.
No securities regulatory authority has either approved or disapproved of the contents of this news release. The securities being offered have not been, and will not be, registered under the United States Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States unless pursuant to an exemption therefrom. This press release is for information purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities of Therapure Biopharma Inc. in any jurisdiction in which such offer, solicitation or sale would be unlawful.
Investor information contact:
David Long, 289-327-2619
Photo courtesy of Shutterstock